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We appreciate the comments by 
Dr. Poullis regarding our recent study 
examining outcomes in patients with 
clinical stage IIIA(N2) non–small-cell 
lung cancer.
We agree that the elimination of 
patients who did not survive 4 months 
from the analysis was a limitation of the 
study. The use of Cox–Aalen regression 
may have mitigated this bias, however, 
it would not control for potential time 
biases because of differences in the 
duration of time it takes to complete 
certain treatment categories.1
Dr. Poullis states that there were 
several covariates affecting survival, 
such as age, laterality, and histology not 
included in the Cox regression analysis. 
In the Methods section we state that 
these variables were included in our 
model and were controlled by stratifica-
tion because of the violation of propor-
tional hazard for these variables. This 
allows for calculation of hazard ratio 
for those variables that do not violate 
the proportional hazard assumption but 
it does preclude the generation of haz-
ard ratio estimates for variables that do 
violate the proportional hazard assump-
tion. Therefore, covariates includ-
ing age, laterality, and histology were 
included as covariates in the model; 
however, specific hazard ratios for each 
of these variables are unavailable.
Table 3 reveals an overlap 
between the confidence intervals for 
patients who underwent neoadjuvant + 
lobectomy versus lobectomy followed 
by adjuvant therapy. However, this table 
only included patients diagnosed in 
2003–2004 (N = 4025) and the purpose 
of these results was to examine whether 
comorbidity significantly affected out-
comes, which it did not. Our initial 
cohort with a larger number of patients 
(N = 10,058) revealed a significant 
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difference in hazard ratios between the 
neoadjuvant + lobectomy and lobec-
tomy followed by adjuvant therapy 
groups. We agree with Dr. Poulis that 
future studies will continue to clarify 
this issue. 
Matthew Koshy, MD
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To the Editor:
We congratulate Pegna et al.1 for 
their very important contribution to the 
field of lung cancer screening by report-
ing the interim results of the Italian 
Lung (ITALUNG) trial, a randomized 
control study for lung cancer screening 
with low-dose computed tomography 
(LDCT) compared with usual care. On 
the basis of the evidence provided by the 
National Lung Screening Trial (NLST),2 
established guidelines, including one 
by the National Comprehensive Cancer 
Network, now recommend screening 
for lung cancer using LDCT in indi-
viduals with high risk. However, many 
issues remain to be solved before these 
research results can be extrapolated to 
community practice. This article pro-
vides clues to overcoming some of 
these issues, as it reports the feasibility 
of mail-based participant recruitment 
and a shared protocol for nodule man-
agement using follow-up CT, 2-fluoro-
2-deoxy-D glucose-positron emission 
tomography, CT-guided fine-needle 
aspiration biopsy, and bronchoscopic 
biopsy. Lung cancer detection rates 
using LDCT are also discussed.
Among 1406 participants who 
were randomly allocated to the LDCT 
screening group and who completed the 
baseline screening, the authors detected 
20 patients with lung tumors at baseline 
(detection rate of 1.5%) and an additional 
18 patients during three annual subse-
quent screening rounds (detection rate 
of 0.5%). The detection rate was signifi-
cantly higher for the baseline compared 
with the subsequent screening rounds, as 
has been similarly shown in other obser-
vational and randomized trials includ-
ing the NLST; this result ostensibly 
seems reasonable because of the accu-
mulated patients with lung cancer who 
are likely present at the baseline screen-
ing. However, this enhanced detection 
at baseline might also be attributed to 
other factors. For example, indolent can-
cers tend to accumulate preferentially 
without presenting symptoms, leading 
to a higher rate of overdiagnosis at base-
line than during subsequent screening 
rounds. In fact, a total of 1060 and 941 
patients with lung cancer were diagnosed 
in the CT and radiograph screening 
groups, respectively, in the NLST.2 The 
difference between these two groups, 
that is, 119 patients, might reflect the 
occurrence of overdiagnosis. According 
to a recent publication3 on the initial 
results of this trial, 292 and 190 patients 
were diagnosed as having lung can-
cer in the CT and radiograph screening 
groups during the first round of screen-
ing, respectively, resulting in a difference 
of 102 patients: as many as 86% (102 of 
119) of the potentially overdiagnosed 
cases of lung cancer originated from the 
initial screening. In other words, overdi-
agnosis may be more infrequent during 
subsequent screening rounds. This argu-
ment may justify repeated lung cancer 
screening efforts using LDCT. We are 
eagerly anticipating the final report by 
the ITALUNG researchers so that we 
can analyze the effect of overdiagnosis 
in lung cancer screening using LDCT.
